PCI Biotech will be presenting at BioTrinity 2015, Novotel London West, May 11-13, 2015
Lysaker, May 12 2015 - PCI Biotech will be presenting at BioTrinity 2015, Novotel London West, May 11-13, 2015.
BioTrinity 2015 is the leading European Biopartnering and Investment Conference. It provides opportunity to meet investors, senior licensing executives from global pharma organisations and senior management of innovative drug development and platform technology companies.
The presentation “An innovative and versatile technology for local cancer treatment, CTL-induction, and macromolecule delivery” will be held 12 May local time 15:10 and the company will be represented by Mr. Gaël L'Hévéder, CBDO.
The presentation will be available at the PCI Biotech’s website, under “News”.
About PCI Biotech
PCI Biotech is a cancer focused biopharmaceutical company headquartered in Norway and listed on the Oslo Stock Exchange (Axess). The company is developing therapeutic products based on its proprietary photochemical internalization (PCI) technology. Originating from world leading research at the Norwegian Radium Hospital, the PCI technology works by inducing triggered endosomal release and may be used to unlock the true therapeutic potential of a wide array of modalities, such as small molecules, ADCs and siRNA. Two programs are currently in clinical development in patient populations with a high unmet medical need; recurrent head and neck cancer (phase II) and bile duct cancer (phase I/II). The company is also developing PCI as a CTL induction technology for therapeutic and prophylactic vaccination. It has been demonstrated both in vivo and ex vivo that PCI significantly increases the number of activated antigen-specific CTLs (Cytotoxic T Lymphocytes) by enhancing the MHC I antigen presentation of antigen presenting cells. When applied more specifically to the emerging field of cancer immunotherapy, PCI can be used to enhance the important cytotoxic effect of therapeutic cancer vaccines. PCI Biotech follows a strategy to create value by improving the effect both of existing cancer drugs and by realizing the large potential in new therapeutics, including therapeutic vaccines.
For more information visit: www.pcibiotech.com
For further information, please contact
Ronny Skuggedal, CFO rs@pcibiotech.no Mobile: +47 9400 5757